Clinical Trials Logo

Tremor clinical trials

View clinical trials related to Tremor.

Filter by:

NCT ID: NCT02037217 Completed - Essential Tremor Clinical Trials

ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential Tremor

Start date: February 2011
Phase: Phase 1
Study type: Interventional

A feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MRI-guided focused ultrasound (MRgFUS) treatment of patients with medication-refractory movement disorders, namely Essential Tremor (ET). This study is designed as a prospective, single site, single arm, nonrandomized study. Assessments will be made before and three months after MRgFUS for clinical symptom relief, quality of life (QoL) improvements, and safety of MRgFUS in the treatment of ET. Similarly, QoL measures will be obtained using Quality of Life in Essential Tremor (QUEST) questionnaire. Relative Safety will be evaluated using a common description of Significant Clinical Complications for patients treated in this study. This study will be performed on the 3T MR scanners. The ExAblate system is a medical device that involves a focused ultrasound system and an MRI scanner. ExAblate delivers a pulse of focused ultrasound energy, or sonication, to the targeted tissue. In this particular study the targeted tissue is a unilateral thermal lesion created in the ventralis intermedius nucleus of the thalamus. The treatment begins with a series of standard diagnostic MR images to identify the location and shape of tumor to be treated. The ExAblate computer uses the physician's designation of the target volume to plan the best way to cover the target volume with small spots called "sonications". These treatment spots are cylinder shaped. Their size depends on sonication power and duration. During the treatment, a specific MR scan, which can be processed to identify changes in tissue temperature, provides a thermal map of the treatment volume to confirm the therapeutic effect. The thermal map is used to monitor the treatment in progress, and confirm that the ablation is proceeding according to plan, thus closing the therapy loop. The ExAblate transcranial operates a helmet-shaped transducer (currently utilizing 1000-element phased array transducer) positioned above the subject head. The ExAblate transcranial system also includes means to immobilize the subject head, cool the interface water, and software for CT analysis and phase correction computation. The ExAblate transcranial system is an experimental device and is being investigated in this study.

NCT ID: NCT01978080 Completed - Essential Tremor Clinical Trials

Continuous Tremor Assessment During Daily Activities

Start date: October 2013
Phase: N/A
Study type: Interventional

The specific aim of this study is to evaluate if tremor severity and quality of life can be improved more using continuous home monitoring along with traditional assessments versus traditional assessments alone.

NCT ID: NCT01961297 Completed - Spasmodic Dysphonia Clinical Trials

Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response

Start date: July 2012
Phase: Phase 2
Study type: Interventional

The proposed research aims to determine brain abnormalities in patients with spasmodic dysphonia (SD) and voice tremor (VT) as the basis for characterization of central mechanisms underlying symptom improvement following the use of sodium oxybate, a novel oral medication for the treatment of ethanol-responsive dystonia. The proposed research is relevant to public health because the elucidation of disorder-specific mechanistic aspects of brain organization in SD vs. SD/VT is ultimately expected to lead to establishment of enhanced criteria for clinical management of these disorders, including differential diagnosis and treatment. Thus, the proposed research is relevant to the part of NIH's mission that pertains to developing fundamental knowledge that will help to reduce the burdens of human disability.

NCT ID: NCT01952678 Completed - Parkinson's Disease Clinical Trials

Compare Rates of Agreement Between Clinical Diagnosis and Visual Assessment of DaTscan™ Images in Non-Caucasian and Caucasian Subjects With Parkinson's Disease (PD) or Essential Tremor (ET)

Start date: July 30, 2013
Phase:
Study type: Observational

The primary objective of this study is to determine if the diagnostic performance of DaTscan™ single photon emission computed tomography (SPECT) imaging is different in non-Caucasian subjects compared with Caucasian subjects with movement disorders.

NCT ID: NCT01945567 Completed - Parkinson's Disease Clinical Trials

Randomised Crossover Trial of DBS of Differential PSA Regions in Parkinson's Disease and Tremor

Start date: August 2012
Phase: Phase 2
Study type: Interventional

The posterior subthalamic area holds promise as a target region for deep brain stimulation in tremor and Parkinson's disease. Using the magnetic resonance-directed implantable guide tube surgical technique, subregions of the posterior subthalamic area can be individually targetted on a single electrode lead trajectory. The hypothesis is that the caudal zona incerta may provide improved control of movement disorder symptoms than the more commonly stimulated dorsal zona incerta.

NCT ID: NCT01932463 Completed - Essential Tremor Clinical Trials

ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) for Treatment of Tremor

Start date: May 2011
Phase: N/A
Study type: Interventional

A feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound for Unilateral Thalamotomy in the Treatment of Tremor

NCT ID: NCT01864525 Completed - Voice Tremor Clinical Trials

Effects of Octanoic Acid for Treatment of Essential Voice Tremor

Start date: July 2013
Phase: Phase 1/Phase 2
Study type: Interventional

Essential voice tremor is a neurological condition that produces a regular, shaking quality in the voice. One form of drug treatment that produces some improvement in tremor of the hands is octanoic acid, which is a food additive that is similar to alcohol. Research suggests that octanoic acid may reduce tremor in the hands/arms with few side effects and no intoxication effects. This study will determine whether octanoic acid may be useful for reducing tremor when it affects the voice. Researchers are hypothesizing that octanoic acid will reduce the effects of tremor on the voice.

NCT ID: NCT01827904 Completed - Essential Tremor Clinical Trials

ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Essential Tremors

Start date: May 2013
Phase: N/A
Study type: Interventional

The objective of this prospective, randomized, double-blind (to subjects, local site's blinded assessor and Tremor Core Lab assessors), crossover, multi-site, two-arm study (ExAblate treated arm Vs ExAblate Sham treated control arm) is to test the efficacy of treatment using the ExAblate Transcranial System and to further demonstrate safety in medication-refractory tremor in subjects with essential tremor (ET).

NCT ID: NCT01731145 Completed - Tremor Clinical Trials

Assessment of Tremor Using SNUMAP Motion Sensing System

SNUMAP
Start date: August 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to record and measure tremor using portable six-axis (tri-axial accelerometer and tri-axial gyroscope) motion sensing system.

NCT ID: NCT01602042 Completed - Essential Tremor Clinical Trials

Adaptive Portable Essential Tremor Monitor

Start date: May 2012
Phase: N/A
Study type: Observational

The purpose of this study is to evaluate the utility of a portable motion sensor-based system designed to monitor essential tremor (ET) to better prescribe therapy to minimize symptoms and expand care for ET patients.